4DMedical Secures CE Mark for CT:VQ, Expands into Europe with A$83M Funding

Event summary

  • 4DMedical's CT:VQ™ received CE Mark certification for commercial use in the European Union on March 31, 2026.
  • The company secured A$83 million in private placement funding to support European expansion.
  • CT:VQ™ is the world's first non-contrast, ventilation-perfusion imaging technology.
  • The European market has approximately 400,000 nuclear VQ scans performed annually.

The big picture

4DMedical's CE Mark certification for CT:VQ™ positions it to capitalize on the European Union's highly developed healthcare infrastructure and extensive installed base of CT scanners. The A$83 million funding round underscores investor confidence in the company's growth strategy, particularly as it seeks to address the clinical need for advanced cardiothoracic imaging. The technology's ability to provide functional lung insights without radiotracers could disrupt traditional nuclear VQ imaging methods, offering operational efficiencies and broader accessibility.

What we're watching

Market Adoption
How quickly CT:VQ™ will be adopted by leading European hospitals and clinicians.
Competitive Positioning
Whether 4DMedical can sustain its lead in non-contrast ventilation-perfusion imaging.
Regulatory Expansion
The pace at which 4DMedical can secure additional regulatory clearances in other major markets.